{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:19:38Z","timestamp":1787685578165,"version":"build-2784847793"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41375-026-03020-2","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:28:31Z","timestamp":1782480511000},"page":"1841-1853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasticity under pressure: biology and detection of lineage switch in acute leukemia"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-6749","authenticated-orcid":false,"given":"Alexandra E.","family":"Kovach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1588-2571","authenticated-orcid":false,"given":"Yang-Yang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Lamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0691-356X","authenticated-orcid":false,"given":"Kathrin","family":"Bernt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-5738","authenticated-orcid":false,"given":"Simon","family":"Bomken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa E.","family":"Brodersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7285-2390","authenticated-orcid":false,"given":"Barbara","family":"Buldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana Delgado","family":"Colon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H. H.","family":"Coorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rula Green","family":"Gladden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1581-1327","authenticated-orcid":false,"given":"Zhaohui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-8942","authenticated-orcid":false,"given":"Elad","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H.","family":"Kurzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Mejstrikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2903-9542","authenticated-orcid":false,"given":"Sunil S.","family":"Raikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-6767","authenticated-orcid":false,"given":"Susan R.","family":"Rheingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K.","family":"Silbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-5567","authenticated-orcid":false,"given":"Kai","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2601-3665","authenticated-orcid":false,"given":"Constance M.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5408-9253","authenticated-orcid":false,"given":"Hao-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1555-2946","authenticated-orcid":false,"given":"Sara","family":"Ghorashian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"3020_CR1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/00062752-200207000-00004","volume":"9","author":"P Ernst","year":"2002","unstructured":"Ernst P, Wang J, Korsmeyer SJ. The role of MLL in hematopoiesis and leukemia. Curr Opin Hematol. 2002;9:282\u20137.","journal-title":"Curr Opin Hematol"},{"key":"3020_CR2","first-page":"2023","volume":"9","author":"SA Ridge","year":"1995","unstructured":"Ridge SA, Cabrera ME, Ford AM, Tapia S, Risueno C, Labra S, et al. Rapid intraclonal switch of lineage dominance in congenital leukaemia with a MLL gene rearrangement. Leukemia. 1995;9:2023\u20136.","journal-title":"Leukemia"},{"key":"3020_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1182\/blood.V64.3.701.701","volume":"64","author":"S Stass","year":"1984","unstructured":"Stass S, Mirro J, Melvin S, Pui CH, Murphy SB, Williams D. Lineage switch in acute leukemia. Blood. 1984;64:701\u20136.","journal-title":"Blood"},{"key":"3020_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2016.10.008","volume":"30","author":"S Lin","year":"2016","unstructured":"Lin S, Luo RT, Ptasinska A, Kerry J, Assi SA, Wunderlich M, et al. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. Cancer Cell. 2016;30:737\u201349.","journal-title":"Cancer Cell"},{"key":"3020_CR5","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ajh.23266","volume":"87","author":"JG Rossi","year":"2012","unstructured":"Rossi JG, Bernasconi AR, Alonso CN, Rubio PL, Gallego MS, Carrara CA, et al. Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am J Hematol. 2012;87:890\u20137.","journal-title":"Am J Hematol"},{"key":"3020_CR6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/blood.2024026655","volume":"146","author":"SK Silbert","year":"2025","unstructured":"Silbert SK, Rankin AW, Hoang CN, Semchenkova A, Myers RM, Zerkalenkova E, et al. Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. Blood. 2025;146:437\u201355.","journal-title":"Blood"},{"key":"3020_CR7","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/pbc.25953","volume":"63","author":"A Rayes","year":"2016","unstructured":"Rayes A, McMasters RL, O\u2019Brien MM. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr Blood Cancer. 2016;63:1113\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"3020_CR8","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406\u201310.","journal-title":"Blood"},{"key":"3020_CR9","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/s41375-025-02723-2","volume":"39","author":"P Amaral","year":"2025","unstructured":"Amaral P, Christie R, Gresham DOF, Lucas EJM, Xu LK, Behrmann L, et al. Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia. Leukemia. 2025;39:2575\u201389.","journal-title":"Leukemia"},{"key":"3020_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/pbc.20722","volume":"46","author":"WL Carroll","year":"2006","unstructured":"Carroll WL, Bhojwani D, Min DJ, Moskowitz N, Raetz EA. Childhood acute lymphoblastic leukemia in the age of genomics. Pediatr Blood Cancer. 2006;46:570\u20138.","journal-title":"Pediatr Blood Cancer"},{"key":"3020_CR11","first-page":"2261","volume":"110","author":"CG Van der Ham","year":"2025","unstructured":"Van der Ham CG, Van Leeuwen FN, Kuiper RP. Treatment-related mutagenic processes in acute lymphoblastic leukemia. Haematologica. 2025;110:2261\u201372.","journal-title":"Haematologica"},{"key":"3020_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood.2019002220","volume":"135","author":"B Li","year":"2020","unstructured":"Li B, Brady SW, Ma X, Shen S, Zhang Y, Li Y, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135:41\u201355.","journal-title":"Blood"},{"key":"3020_CR13","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-15-1015","volume":"76","author":"JE Farrar","year":"2016","unstructured":"Farrar JE, Schuback HL, Ries RE, Wai D, Hampton OA, Trevino LR, et al. Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse. Cancer Res. 2016;76:2197\u2013205.","journal-title":"Cancer Res"},{"key":"3020_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7604","volume":"6","author":"X Ma","year":"2015","unstructured":"Ma X, Edmonson M, Yergeau D, Muzny DM, Hampton OA, Rusch M, et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun. 2015;6:6604.","journal-title":"Nat Commun"},{"key":"3020_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1053\/j.seminhematol.2025.06.005","volume":"62","author":"L Guarnera","year":"2025","unstructured":"Guarnera L, Fabiani E, Silvestrini G, Attardi E, Voso MT. Secondary and therapy-related acute myeloid leukemias: overlapping features, distinct trajectories. Semin Hematol. 2025;62:155\u201366.","journal-title":"Semin Hematol"},{"key":"3020_CR16","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt \u00d8stg\u00e5rd","year":"2015","unstructured":"Granfeldt \u00d8stg\u00e5rd LS, Medeiros BC, Sengel\u00f8v H, N\u00f8rgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33:3641\u20139.","journal-title":"J Clin Oncol"},{"key":"3020_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/MOH.0000000000000316","volume":"24","author":"A Ganser","year":"2017","unstructured":"Ganser A, Heuser M. Therapy-related myeloid neoplasms. Curr Opin Hematol. 2017;24:152\u20138.","journal-title":"Curr Opin Hematol"},{"key":"3020_CR18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518:552\u20135.","journal-title":"Nature"},{"key":"3020_CR19","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1080\/10428194.2024.2376166","volume":"65","author":"AE Kovach","year":"2024","unstructured":"Kovach AE, Komova D, Itov A, Gaskova M, Kalinina I, Voronin K, et al. Pediatric therapy-related hematologic neoplasms show enrichment for KMT2A rearrangement and lymphoblastic phenotype. Leuk Lymphoma. 2024;65:1840\u201352.","journal-title":"Leuk Lymphoma"},{"key":"3020_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21255-8","volume":"12","author":"JR Schwartz","year":"2021","unstructured":"Schwartz JR, Ma J, Kamens J, Westover T, Walsh MP, Brady SW, et al. The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. Nat Commun. 2021;12:985.","journal-title":"Nat Commun"},{"key":"3020_CR21","unstructured":"Schneider K, Zelley K, Nichols KE, Schwartz Levine A, Garber J Li-Fraumeni Syndrome. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews((R)). Seattle (WA) 1993."},{"key":"3020_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood.2019000937","volume":"136","author":"AL Brown","year":"2020","unstructured":"Brown AL, Hahn CN, Scott HS. Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA). Blood. 2020;136:24\u201335.","journal-title":"Blood"},{"key":"3020_CR23","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1080\/10428194.2023.2232496","volume":"64","author":"F Locatelli","year":"2023","unstructured":"Locatelli F, Shah B, Thomas T, Velasco K, Adedokun B, Aldoss I, et al. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R\/R BCP acute lymphoblastic leukemia: a review. Leuk Lymphoma. 2023;64:1615\u201333.","journal-title":"Leuk Lymphoma"},{"key":"3020_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","volume":"7","author":"AJ Lamble","year":"2023","unstructured":"Lamble AJ, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, et al. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023;7:575\u201385.","journal-title":"Blood Adv"},{"key":"3020_CR25","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","volume":"35","author":"ME Dourthe","year":"2021","unstructured":"Dourthe ME, Rabian F, Yakouben K, Chevillon F, Cabannes-Hamy A, Mechinaud F, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. 2021;35:3383\u201393.","journal-title":"Leukemia"},{"key":"3020_CR26","doi-asserted-by":"publisher","first-page":"E216","DOI":"10.1002\/ajh.26983","volume":"98","author":"EM Fenu","year":"2023","unstructured":"Fenu EM, Margolskee E, Pillai V. Transdifferentiation of B-lymphoblastic leukemia to histiocytic sarcoma after immunotherapy. Am J Hematol. 2023;98:E216\u2013E8.","journal-title":"Am J Hematol"},{"key":"3020_CR27","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41379-020-00673-x","volume":"34","author":"C Egan","year":"2021","unstructured":"Egan C, Lack J, Skarshaug S, Pham TA, Abdullaev Z, Xi L, et al. The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy. Mod Pathol. 2021;34:336\u201347.","journal-title":"Mod Pathol"},{"key":"3020_CR28","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/emmm.201302834","volume":"5","author":"G Regalo","year":"2013","unstructured":"Regalo G, Leutz A. Hacking cell differentiation: transcriptional rerouting in reprogramming, lineage infidelity and metaplasia. EMBO Mol Med. 2013;5:1154\u201364.","journal-title":"EMBO Mol Med"},{"key":"3020_CR29","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/ajcp\/aqad022","volume":"159","author":"W Xiao","year":"2023","unstructured":"Xiao W, Amador C, Cook JR, Czader M, Dave S, Dogan A, et al. B-cell lineage neoplasms transdifferentiating into histiocytic\/dendritic cell neoplasms: diversity, differentiation lineage, genomic alterations, and therapy: Report from the 2021 SH\/EAHP Workshop. Am J Clin Pathol. 2023;159:522\u201337.","journal-title":"Am J Clin Pathol"},{"key":"3020_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S1470-2045(04)01428-7","volume":"5","author":"AL Feldman","year":"2004","unstructured":"Feldman AL, Minniti C, Santi M, Downing JR, Raffeld M, Jaffe ES. Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin. Lancet Oncol. 2004;5:248\u201350.","journal-title":"Lancet Oncol"},{"key":"3020_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood.V67.1.1.1","volume":"67","author":"MF Greaves","year":"1986","unstructured":"Greaves MF, Chan LC, Furley AJ, Watt SM, Molgaard HV. Lineage promiscuity in hemopoietic differentiation and leukemia. Blood. 1986;67:1\u201311.","journal-title":"Blood"},{"key":"3020_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood.V62.1.1.1","volume":"62","author":"EA McCulloch","year":"1983","unstructured":"McCulloch EA. Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982). Blood. 1983;62:1\u201313.","journal-title":"Blood"},{"key":"3020_CR33","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1182\/blood.V61.6.1138.1138","volume":"61","author":"LJ Smith","year":"1983","unstructured":"Smith LJ, Curtis JE, Messner HA, Senn JS, Furthmayr H, McCulloch EA. Lineage infidelity in acute leukemia. Blood. 1983;61:1138\u201345.","journal-title":"Blood"},{"key":"3020_CR34","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1182\/blood.2021013442","volume":"139","author":"C Chen","year":"2022","unstructured":"Chen C, Yu W, Alikarami F, Qiu Q, Chen CH, Flournoy J, et al. Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia. Blood. 2022;139:2198\u2013211.","journal-title":"Blood"},{"key":"3020_CR35","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1182\/blood.2024027270","volume":"145","author":"C Chen","year":"2025","unstructured":"Chen C, Xu J, Sussman JH, Vincent T, Tumulty JS, Yoshimura S, et al. Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome. Blood. 2025;145:2685\u2013700.","journal-title":"Blood"},{"key":"3020_CR36","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/s43018-025-00987-2","volume":"6","author":"I Iacobucci","year":"2025","unstructured":"Iacobucci I, Zeng AGX, Gao Q, Garcia-Prat L, Baviskar P, Shah S, et al. Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features. Nat Cancer. 2025;6:1242\u201362.","journal-title":"Nat Cancer"},{"key":"3020_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nri3570","volume":"14","author":"MR Clark","year":"2013","unstructured":"Clark MR, Mandal M, Ochiai K, Singh H. Orchestrating B cell lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor signalling. Nat Rev Immunol. 2013;14:1\u201312.","journal-title":"Nat Rev Immunol"},{"key":"3020_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev.immunol.22.012703.104807","volume":"22","author":"M Busslinger","year":"2004","unstructured":"Busslinger M. Transcriptional control of early B cell development 1. Annu Rev Immunol. 2004;22:55\u201379.","journal-title":"Annu Rev Immunol"},{"key":"3020_CR39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0092-8674(04)00419-2","volume":"117","author":"H Xie","year":"2004","unstructured":"Xie H, Ye M, Feng R, Graf T. Stepwise reprogramming of B cells into macrophages. Cell. 2004;117:663\u201376.","journal-title":"Cell"},{"key":"3020_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58868-2","volume":"16","author":"P Domizi","year":"2025","unstructured":"Domizi P, Sarno J, Jager A, Merchant M, Pacheco KZB, Yamada-Hunter SA, et al. IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies. Nat Commun. 2025;16:3800.","journal-title":"Nat Commun"},{"key":"3020_CR41","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1182\/blood-2012-03-414821","volume":"120","author":"S Simmons","year":"2012","unstructured":"Simmons S, Knoll M, Drewell C, Wolf I, Mollenkopf HJ, Bouquet C, et al. Biphenotypic B-lymphoid\/myeloid cells expressing low levels of Pax5: potential targets of BAL development. Blood. 2012;120:3688\u201398.","journal-title":"Blood"},{"key":"3020_CR42","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1126\/science.1240831","volume":"341","author":"HY Kueh","year":"2013","unstructured":"Kueh HY, Champhekar A, Nutt SL, Elowitz MB, Rothenberg EV. Positive feedback between PU.1 and the cell cycle controls myeloid differentiation. Science. 2013;341:670\u20133.","journal-title":"Science"},{"key":"3020_CR43","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1073\/pnas.1413383112","volume":"112","author":"JS McClellan","year":"2015","unstructured":"McClellan JS, Dove C, Gentles AJ, Ryan CE, Majeti R. Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages. Proc Natl Acad Sci USA. 2015;112:4074\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3020_CR44","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-21-0502","volume":"13","author":"MH Linde","year":"2023","unstructured":"Linde MH, Fan AC, Kohnke T, Trotman-Grant AC, Gurev SF, Phan P, et al. Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy. Cancer Discov. 2023;13:1164\u201385.","journal-title":"Cancer Discov"},{"key":"3020_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320","volume":"7","author":"E Jacoby","year":"2016","unstructured":"Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H, et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 2016;7:12320.","journal-title":"Nat Commun"},{"key":"3020_CR46","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/ijlh.13923","volume":"44","author":"JH Kurzer","year":"2022","unstructured":"Kurzer JH, Weinberg OK. To B- or not to B-: A review of lineage switched acute leukemia. Int J Lab Hematol. 2022;44:64\u201370.","journal-title":"Int J Lab Hematol"},{"key":"3020_CR47","doi-asserted-by":"publisher","first-page":"e00220","DOI":"10.1097\/BS9.0000000000000220","volume":"7","author":"Q Zhou","year":"2025","unstructured":"Zhou Q, Wang Y. A shadow in the treatment of acute leukemia: lineage switch. Blood Sci. 2025;7:e00220.","journal-title":"Blood Sci"},{"key":"3020_CR48","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1182\/blood.2021015036","volume":"140","author":"R Tirtakusuma","year":"2022","unstructured":"Tirtakusuma R, Szoltysek K, Milne P, Grinev VV, Ptasinska A, Chin PS, et al. Epigenetic regulator genes direct lineage switching in MLL\/AF4 leukemia. Blood. 2022;140:1875\u201390.","journal-title":"Blood"},{"key":"3020_CR49","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41591-022-01720-7","volume":"28","author":"E Khabirova","year":"2022","unstructured":"Khabirova E, Jardine L, Coorens THH, Webb S, Treger TD, Engelbert J, et al. Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia. Nat Med. 2022;28:743\u201351.","journal-title":"Nat Med"},{"key":"3020_CR50","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41375-024-02164-3","volume":"38","author":"R Tirtakusuma","year":"2024","unstructured":"Tirtakusuma R, Milne P, Blair HJ, Shi Y, Bomken S, Heidenreich O. Fusion transcripts are present in early progenitor cells in KMT2A-rearranged B-ALL. Leukemia. 2024;38:883\u20136.","journal-title":"Leukemia"},{"key":"3020_CR51","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","volume":"37","author":"C Meyer","year":"2023","unstructured":"Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gr\u00f6ger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37:988\u20131005.","journal-title":"Leukemia"},{"key":"3020_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53399-8","volume":"15","author":"DH Janssens","year":"2024","unstructured":"Janssens DH, Duran M, Otto DJ, Wu W, Xu Y, Kirkey D, et al. MLL oncoprotein levels influence leukemia lineage identities. Nat Commun. 2024;15:9341.","journal-title":"Nat Commun"},{"key":"3020_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41375-024-02428-y","volume":"39","author":"Z Li","year":"2025","unstructured":"Li Z, Fierstein S, Tanaka-Yano M, Frenis K, Chen CC, Wang D, et al. The epigenetic state of the cell of origin defines mechanisms of leukemogenesis. Leukemia. 2025;39:87\u201397.","journal-title":"Leukemia"},{"key":"3020_CR54","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nature04980","volume":"442","author":"AV Krivtsov","year":"2006","unstructured":"Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442:818\u201322.","journal-title":"Nature"},{"key":"3020_CR55","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/s43018-023-00604-0","volume":"4","author":"THH Coorens","year":"2023","unstructured":"Coorens THH, Collord G, Treger TD, Adams S, Mitchell E, Newman B, et al. Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy. Nat Cancer. 2023;4:1095\u2013101.","journal-title":"Nat Cancer"},{"key":"3020_CR56","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41375-024-02449-7","volume":"39","author":"S Qiu","year":"2025","unstructured":"Qiu S, Mei Y, Gu R, Liu Y, Chen M, Xing H, et al. The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients. Leukemia. 2025;39:238\u201342.","journal-title":"Leukemia"},{"key":"3020_CR57","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1182\/blood-2024-209607","volume":"144","author":"V Sad\u00edlek","year":"2024","unstructured":"Sad\u00edlek V, Cabalkova B, Skotnicova A, Reiterova M, Vaskova M, Zaliova M, et al. Single-cell multiomics reveals a shared mechanism of lineage switch in DUX4r, ZNF384r, and PAX5 P80R subtypes of pediatric acute lymphoblastic leukemia. Blood. 2024;144:635.","journal-title":"Blood"},{"key":"3020_CR58","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1182\/blood.2024026482","volume":"145","author":"YY Ding","year":"2025","unstructured":"Ding YY, Sussman JH, Madden K, Loftus JP, Chen RK, Falkenstein CD, et al. Targeting senescent stemlike subpopulations in Philadelphia chromosome-like acute lymphoblastic leukemia. Blood. 2025;145:1195\u2013210.","journal-title":"Blood"},{"key":"3020_CR59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2217\/ijh.13.20","volume":"2","author":"AG Muntean","year":"2013","unstructured":"Muntean AG. Mechanisms of mixed-lineage leukemia. Int J Hematol Oncol. 2013;2:207\u201317.","journal-title":"Int J Hematol Oncol"},{"key":"3020_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00786-y","volume":"13","author":"S Zehtabcheh","year":"2025","unstructured":"Zehtabcheh S, Soleimani Samarkhazan H, Asadi M, Zabihi M, Parkhideh S, Mohammadi MH. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. Biomark Res. 2025;13:73.","journal-title":"Biomark Res"},{"key":"3020_CR61","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2253","volume":"7","author":"AV Krivtsov","year":"2007","unstructured":"Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7:823\u201333.","journal-title":"Nat Rev Cancer"},{"key":"3020_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.799982","volume":"12","author":"R Takeda","year":"2022","unstructured":"Takeda R, Yokoyama K, Fukuyama T, Kawamata T, Ito M, Yusa N, et al. Repeated lineage switches in an elderly case of refractory B-cell acute lymphoblastic leukemia with MLL gene amplification: a case report and literature review. Front Oncol. 2022;12:799982.","journal-title":"Front Oncol"},{"key":"3020_CR63","doi-asserted-by":"crossref","unstructured":"G\u00f3recki M, Kozio\u0142 I, Kopystecka A, Budzy\u0144ska J, Zawitkowska J, Lejman M. Updates in KMT2A gene rearrangement in pediatric acute lymphoblastic leukemia. Biomedicines. 2023;11:821.","DOI":"10.3390\/biomedicines11030821"},{"key":"3020_CR64","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"3020_CR65","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"3020_CR66","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"3020_CR67","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","volume":"129","author":"L Hovorkova","year":"2017","unstructured":"Hovorkova L, Zaliova M, Venn NC, Bleckmann K, Trkova M, Potuckova E, et al. Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Blood. 2017;129:2771\u201381.","journal-title":"Blood"},{"key":"3020_CR68","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/ajh.26949","volume":"98","author":"NJ Short","year":"2023","unstructured":"Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, et al. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023;98:1196\u2013203.","journal-title":"Am J Hematol"},{"key":"3020_CR69","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41375-022-01736-5","volume":"37","author":"J Senapati","year":"2023","unstructured":"Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia. 2023;37:5\u201317.","journal-title":"Leukemia"},{"key":"3020_CR70","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1365-2141.1976.tb00188.x","volume":"34","author":"MD Beard","year":"1976","unstructured":"Beard MD, Durrant J, Catovsky D, Wiltshaw E, Amess JL, Brearley RL, et al. Blast crisis of chronic myeloid leukaemia (CML). I. Presentation simulating acute lymphoid leukaemia (ALL). Br J Haematol. 1976;34:167\u201378.","journal-title":"Br J Haematol"},{"key":"3020_CR71","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/blood.V44.3.449.449","volume":"44","author":"DR Boggs","year":"1974","unstructured":"Boggs DR. Editorial: Hematopoietic stem cell theory in relation to possible lymphoblastic conversion of chronic myeloid leukemia. Blood. 1974;44:449\u201353.","journal-title":"Blood"},{"key":"3020_CR72","first-page":"795","volume":"10","author":"J Anastasi","year":"1996","unstructured":"Anastasi J, Feng J, Dickstein JI, Le Beau MM, Rubin CM, Larson RA, et al. Lineage involvement by BCR\/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia. Leukemia. 1996;10:795\u2013802.","journal-title":"Leukemia"},{"key":"3020_CR73","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-2141.1979.tb01161.x","volume":"42","author":"D Catovsky","year":"1979","unstructured":"Catovsky D. Ph1-positive acute leukaemia and chronic granulocytic leukaemia: one or two diseases? Br J Haematol. 1979;42:493\u20138.","journal-title":"Br J Haematol"},{"key":"3020_CR74","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood-2017-05-782888","volume":"130","author":"I Nagel","year":"2017","unstructured":"Nagel I, Bartels M, Duell J, Oberg HH, Ussat S, Bruckmueller H, et al. Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood. 2017;130:2027\u201331.","journal-title":"Blood"},{"key":"3020_CR75","doi-asserted-by":"crossref","unstructured":"Jamieson CH. Chronic myeloid leukemia stem cells. Hematology Am Soc Hematol Educ Program. 2008:436\u201342.","DOI":"10.1182\/asheducation-2008.1.436"},{"key":"3020_CR76","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ajcp\/aqaa208","volume":"155","author":"O Pozdnyakova","year":"2021","unstructured":"Pozdnyakova O, Orazi A, Kelemen K, King R, Reichard KK, Craig FE, et al. Myeloid\/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2. Am J Clin Pathol. 2021;155:160\u201378.","journal-title":"Am J Clin Pathol"},{"key":"3020_CR77","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/ajcp\/aqad135","volume":"161","author":"SJ McKeague","year":"2024","unstructured":"McKeague SJ, O\u2019Rourke K, Fanning S, Joy C, Throp D, Adams R, et al. Acute leukemia with cytogenetically cryptic FGFR1 rearrangement and lineage switch during therapy: A case report and literature review. Am J Clin Pathol. 2024;161:197\u2013205.","journal-title":"Am J Clin Pathol"},{"key":"3020_CR78","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1158\/2643-3230.BCD-21-0163","volume":"3","author":"KM Dickerson","year":"2022","unstructured":"Dickerson KM, Qu C, Gao Q, Iacobucci I, Gu Z, Yoshihara H, et al. ZNF384 fusion oncoproteins drive lineage aberrancy in acute leukemia. Blood Cancer Discov. 2022;3:240\u201363.","journal-title":"Blood Cancer Discov"},{"key":"3020_CR79","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3324\/haematol.2016.151035","volume":"102","author":"S Hirabayashi","year":"2017","unstructured":"Hirabayashi S, Ohki K, Nakabayashi K, Ichikawa H, Momozawa Y, Okamura K, et al. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype. Haematologica. 2017;102:118\u201329.","journal-title":"Haematologica"},{"key":"3020_CR80","unstructured":"UniProt. Q8TF68 ZN384_Human [Available from: https:\/\/www.uniprot.org\/uniprotkb\/Q8TF68\/entry#disease_variants."},{"key":"3020_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00983-2","volume":"14","author":"T Zhou","year":"2024","unstructured":"Zhou T, Curry CV, Khanlari M, Shi M, Cui W, Peker D, et al. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood Cancer J. 2024;14:19.","journal-title":"Blood Cancer J"},{"key":"3020_CR82","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3109\/10428194.2012.753450","volume":"54","author":"S Grammatico","year":"2013","unstructured":"Grammatico S, Vitale A, La Starza R, Gorello P, Angelosanto N, Negulici AD, et al. Lineage switch from pro-B acute lymphoid leukemia to acute myeloid leukemia in a case with t(12;17)(p13;q11)\/TAF15-ZNF384 rearrangement. Leuk Lymphoma. 2013;54:1802\u20135.","journal-title":"Leuk Lymphoma"},{"key":"3020_CR83","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-018-0436-0","volume":"562","author":"TB Alexander","year":"2018","unstructured":"Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018;562:373\u20139.","journal-title":"Nature"},{"key":"3020_CR84","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524\u201339.","journal-title":"Haematologica"},{"key":"3020_CR85","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.3324\/haematol.2020.250423","volume":"106","author":"M Novakova","year":"2021","unstructured":"Novakova M, Zaliova M, Fiser K, Vakrmanova B, Slamova L, Musilova A, et al. DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch. Haematologica. 2021;106:2066\u201375.","journal-title":"Haematologica"},{"key":"3020_CR86","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27265","volume":"65","author":"MJ Oberley","year":"2018","unstructured":"Oberley MJ, Gaynon PS, Bhojwani D, Pulsipher MA, Gardner RA, Hiemenz MC, et al. Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65:e27265.","journal-title":"Pediatr Blood Cancer"},{"key":"3020_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.632532","volume":"11","author":"YZ Qin","year":"2021","unstructured":"Qin YZ, Jiang Q, Xu LP, Wang Y, Jiang H, Dao FT, et al. The prognostic significance of ZNF384 fusions in adult Ph-negative B-cell precursor acute lymphoblastic leukemia: a comprehensive cohort study from a single Chinese center. Front Oncol. 2021;11:632532.","journal-title":"Front Oncol"},{"key":"3020_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11790","volume":"7","author":"H Lilljebj\u00f6rn","year":"2016","unstructured":"Lilljebj\u00f6rn H, Henningsson R, Hyrenius-Wittsten A, Olsson L, Orsmark-Pietras C, von Palffy S, et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016;7:11790.","journal-title":"Nat Commun"},{"key":"3020_CR89","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/ng.3535","volume":"48","author":"T Yasuda","year":"2016","unstructured":"Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet. 2016;48:569\u201374.","journal-title":"Nat Genet"},{"key":"3020_CR90","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41375-025-02758-5","volume":"39","author":"J Bakewell","year":"2025","unstructured":"Bakewell J, Moorman AV, Ryan SL. DUX4-rearranged B-ALL: deciphering a biological and clinical conundrum. Leukemia. 2025;39:2835\u201347.","journal-title":"Leukemia"},{"key":"3020_CR91","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/ng.3691","volume":"48","author":"J Zhang","year":"2016","unstructured":"Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016;48:1481\u20139.","journal-title":"Nat Genet"},{"key":"3020_CR92","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.3324\/haematol.2018.214353","volume":"104","author":"D Schinnerl","year":"2019","unstructured":"Schinnerl D, Mejstrikova E, Schumich A, Zaliova M, Fortschegger K, Nebral K, et al. CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia. Haematologica. 2019;104:e352\u2013e5.","journal-title":"Haematologica"},{"key":"3020_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31507","volume":"72","author":"L Han","year":"2025","unstructured":"Han L, Zheng R, Fuda F, Cantu MD, Koduru P, Jaso JM, et al. Genomic and Clinicopathological Characterization of CRLF2-Rearranged Mixed Phenotype Acute Leukemia. Pediatr Blood Cancer. 2025;72:e31507.","journal-title":"Pediatr Blood Cancer"},{"key":"3020_CR94","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/ajcp\/aqx111","volume":"148","author":"SM Choi","year":"2017","unstructured":"Choi SM, Frederiksen JK, Ross CW, Bixby DL, Shao L. Philadelphia Chromosome-like Mixed-Phenotype Acute Leukemia Demonstrating P2RY8-CRLF2 Fusion and JAK1 Mutation. Am J Clin Pathol. 2017;148:523\u20138.","journal-title":"Am J Clin Pathol"},{"key":"3020_CR95","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/blood-2024-198961","volume":"144","author":"AE Kovach","year":"2024","unstructured":"Kovach AE, Silbert SK, Luong A, Lu G, Lu M, Wang H-W, et al. Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch. Blood. 2024;144:2799.","journal-title":"Blood"},{"key":"3020_CR96","doi-asserted-by":"crossref","unstructured":"Silbert SK, Scanlon S, Wang HW, Yuan CM, Doverte A, Wellek J, et al. CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy. J Immunother Cancer. 2024;12:e009499.","DOI":"10.1136\/jitc-2024-009499"},{"key":"3020_CR97","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41588-023-01429-4","volume":"55","author":"JC Kim","year":"2023","unstructured":"Kim JC, Chan-Seng-Yue M, Ge S, Zeng AGX, Ng K, Gan OI, et al. Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia. Nat Genet. 2023;55:1186\u201397.","journal-title":"Nat Genet"},{"key":"3020_CR98","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021012727","volume":"139","author":"AB Leahy","year":"2022","unstructured":"Leahy AB, Devine KJ, Li Y, Liu H, Myers R, DiNofia A, et al. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood. 2022;139:2173\u201385.","journal-title":"Blood"},{"key":"3020_CR99","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/bloodadvances.2024014986","volume":"9","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Li S, Zhang J, Clark MC, Agrawal V, Pourhassan H, et al. TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL. Blood Adv. 2025;9:2159\u201372.","journal-title":"Blood Adv"},{"key":"3020_CR100","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1158\/1078-0432.CCR-21-0553","volume":"27","author":"YY Ding","year":"2021","unstructured":"Ding YY, Kim H, Madden K, Loftus JP, Chen GM, Allen DH, et al. Network analysis reveals synergistic genetic dependencies for rational combination therapy in Philadelphia chromosome-like acute lymphoblastic leukemia. Clin Cancer Res. 2021;27:5109\u201322.","journal-title":"Clin Cancer Res"},{"key":"3020_CR101","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-18-0236","volume":"79","author":"E Diaz-Flores","year":"2019","unstructured":"Diaz-Flores E, Comeaux EQ, Kim KL, Melnik E, Beckman K, Davis KL, et al. Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia. Cancer Res. 2019;79:2339\u201351.","journal-title":"Cancer Res"},{"key":"3020_CR102","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147\u201356.","journal-title":"Lancet Oncol"},{"key":"3020_CR103","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","volume":"632","author":"P Polonen","year":"2024","unstructured":"Polonen P, Di Giacomo D, Seffernick AE, Elsayed A, Kimura S, Benini F, et al. The genomic basis of childhood T-lineage acute lymphoblastic leukaemia. Nature. 2024;632:1082\u201391.","journal-title":"Nature"},{"key":"3020_CR104","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/2159-8290.CD-21-0145","volume":"11","author":"LE Montefiori","year":"2021","unstructured":"Montefiori LE, Bendig S, Gu Z, Chen X, Polonen P, Ma X, et al. Enhancer hijacking drives oncogenic BCL11B expression in lineage-ambiguous stem cell leukemia. Cancer Discov. 2021;11:2846\u201367.","journal-title":"Cancer Discov"},{"key":"3020_CR105","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood-2021-150841","volume":"138","author":"D Di Giacomo","year":"2021","unstructured":"Di Giacomo D, La Starza R, Gorello P, Pellanera F, Kalender Atak Z, De Keersmaecker K, et al. 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia. Blood. 2021;138:773\u201384.","journal-title":"Blood"},{"key":"3020_CR106","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2423324","volume":"29","author":"JN Wang","year":"2024","unstructured":"Wang JN, Ye B, Cheng F, Yang L, Hu Y, Zheng G, et al. PICALM-MLLT10 fusion gene in hematological neoplasms: clinical features, current practices, and prognoses. Hematology. 2024;29:2423324.","journal-title":"Hematology"},{"key":"3020_CR107","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cancergencyto.2010.07.126","volume":"202","author":"NM Savage","year":"2010","unstructured":"Savage NM, Kota V, Manaloor EJ, Kulharya AS, Pierini V, Mecucci C, et al. Acute leukemia with PICALM-MLLT10 fusion gene: diagnostic and treatment struggle. Cancer Genet Cytogenet. 2010;202:129\u201332.","journal-title":"Cancer Genet Cytogenet"},{"key":"3020_CR108","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/sj.leu.2405074","volume":"22","author":"D Caudell","year":"2008","unstructured":"Caudell D, Aplan PD. The role of CALM-AF10 gene fusion in acute leukemia. Leukemia. 2008;22:678\u201385.","journal-title":"Leukemia"},{"key":"3020_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2024.07.003","volume":"151","author":"J Wang","year":"2024","unstructured":"Wang J, Zhang W, Xu X, Buglioni A, Li P, Chen X, et al. Clinicopathologic features and outcomes of acute leukemia harboring PICALM::MLLT10 fusion. Hum Pathol. 2024;151:105626.","journal-title":"Hum Pathol"},{"key":"3020_CR110","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1182\/bloodadvances.2023010805","volume":"8","author":"O Abla","year":"2024","unstructured":"Abla O, Ries RE, Triche T Jr, Gerbing RB, Hirsch B, Raimondi S, et al. Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood Adv. 2024;8:2005\u201317.","journal-title":"Blood Adv"},{"key":"3020_CR111","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/bjh.19067","volume":"204","author":"C Mark","year":"2024","unstructured":"Mark C, Meshinchi S, Joyce B, Gibson B, Harrison C, Bergmann AK, et al. Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias. Br J Haematol. 2024;204:576\u201384.","journal-title":"Br J Haematol"},{"key":"3020_CR112","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1182\/blood-2024-210504","volume":"144","author":"R Mehta","year":"2024","unstructured":"Mehta R, Chen C, Alikarami F, Foltz S, Loren A, Li E, et al. Multimodal single-cell profiling of minimal residual disease in B acute lymphoblastic leukemia reveals genetic and non-genetic factors of early drug resistance. Blood. 2024;144:316.","journal-title":"Blood"},{"key":"3020_CR113","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","volume":"388","author":"IM van der Sluis","year":"2023","unstructured":"van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med. 2023;388:1572\u201381.","journal-title":"N Engl J Med"},{"key":"3020_CR114","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.1182\/bloodadvances.2025015881","volume":"9","author":"S John","year":"2025","unstructured":"John S, Curran KJ, Hall EM, Keating AK, Baumeister SHC, Nikiforow S, et al. Real-world data for tisagenlecleucel in patients with R\/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv. 2025;9:5249\u201362.","journal-title":"Blood Adv"},{"key":"3020_CR115","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/leu.2015.246","volume":"30","author":"EM Driessen","year":"2016","unstructured":"Driessen EM, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, et al. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia. 2016;30:1184\u20137.","journal-title":"Leukemia"},{"key":"3020_CR116","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","volume":"9","author":"S Ghorashian","year":"2022","unstructured":"Ghorashian S, Jacoby E, De Moerloose B, Rives S, Bonney D, Shenton G, et al. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study. Lancet Haematol. 2022;9:e766\u2013e75.","journal-title":"Lancet Haematol"},{"key":"3020_CR117","first-page":"2275","volume":"141","author":"OK Weinberg","year":"2023","unstructured":"Weinberg OK, Arber DA, Dohner H, Mullighan CG, Orgel E, Porwit A, et al. The International Consensus Classification of acute leukemias of ambiguous lineage. Blood. 2023;141:2275\u20137.","journal-title":"Blood"},{"key":"3020_CR118","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s11033-025-10527-x","volume":"52","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, Zehtabcheh S, Peyvasteh S, Mohammadi MH. C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia. Mol Biol Rep. 2025;52:464.","journal-title":"Mol Biol Rep"},{"key":"3020_CR119","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54:1376\u201389.","journal-title":"Nat Genet"},{"key":"3020_CR120","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2643-3230.BCD-20-0229","volume":"2","author":"S Jeha","year":"2021","unstructured":"Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, et al. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2021;2:326\u201337.","journal-title":"Blood Cancer Discov"},{"key":"3020_CR121","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/ajcp\/aqx055","volume":"148","author":"B Wu","year":"2017","unstructured":"Wu B, Jug R, Luedke C, Su P, Rehder C, McCall C, et al. Lineage switch between b-lymphoblastic leukemia and acute myeloid leukemia intermediated by \u201cOccult\u201d myelodysplastic neoplasm: two cases of adult patients with evidence of genomic instability and clonal selection by chemotherapy. Am J Clin Pathol. 2017;148:136\u201347.","journal-title":"Am J Clin Pathol"},{"key":"3020_CR122","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1158\/1078-0432.CCR-25-1587","volume":"31","author":"ZM Avigan","year":"2025","unstructured":"Avigan ZM, Catlett J, Bodnar S, Pan D, Aleman A, Sheng T, et al. Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy. Clin Cancer Res. 2025;31:4333\u201344.","journal-title":"Clin Cancer Res"},{"key":"3020_CR123","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix T, Alhomoud M, Shouval R, Cliff ERS, Perales MA, Cordas Dos Santos DM, et al. Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients. Clin Cancer Res. 2024;30:4690\u2013700.","journal-title":"Clin Cancer Res"},{"key":"3020_CR124","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s43018-024-00863-5","volume":"6","author":"J Xu","year":"2025","unstructured":"Xu J, Chen C, Sussman JH, Yoshimura S, Vincent T, Polonen P, et al. A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia. Nat Cancer. 2025;6:102\u201322.","journal-title":"Nat Cancer"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03020-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03020-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03020-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:02:20Z","timestamp":1787684540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03020-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":124,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3020"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03020-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BB participated in a speaker\u2019s bureau over the last 2 years: Amgen S.r.l (Milano), Beckman Coulter SRL (Milano). SRR consulted for Pfizer and Abbvie. SG receives honoraria from Novartis, has a patent with UCLB and royalties, serves on a trial steering committee for Autolus and receives honoraria. NNS has received research funding from Lentigen, VOR Bio, and CARGO Therapeutics; has attended advisory board meetings (no honoraria) for VOR, ImmunoACT, and Sobi; and has received royalties from NIH. KLD is supported by the Anne T. and Robert M. Bass Endowed Faculty Scholar in Pediatric Cancer and Blood Disease and the Harriet and Mary Zelencik Endowment. COI: Advisory board for Jazz Pharmaceuticals, research funding from BD Biosciences.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}